AbbVie

AbbVie is a global biopharmaceutical company with a dominant immunology franchise built on monoclonal antibody (mAb) biologics — Skyrizi (IL-23 inhibitor) and Rinvoq (JAK1 inhibitor) — plus neuroscience (Vraylar, Botox Therapeutic, migraine) and oncology assets. The company successfully navigated the largest patent cliff in pharma history (Humira LOE 2023) and replaced it with two higher-growth biologics.

AbbVie remains an immunology-led biopharma: Skyrizi and Rinvoq anchor the franchise, Humira is now runoff, and neuroscience/oncology provide second-line cash flow.

• monetization model: Product sales of branded prescription drugs to wholesalers; plus licensing/collaboration revenue; not subscription/SaaS. (10-K Business, Note 2; sec.gov ; accession 0001551152-25-000012)
• revenue mix: Immunology ~47%, Neuroscience ~17%, Oncology ~12%, Aesthetics ~10%, Other ~15% (FY2024). (10-K Note 14 Segment Information; same URL/accession)
• who pays: Wholesale distributors invoice AbbVie; economic payers are insurers/PBMs, government programs, patients. (10-K Business; Risk Factors; same URL/accession)
• margin_value_capture: GAAP gross margin ~68%; operating margin ~18% incl. acquired IPR&D, ~30% ex-IPR&D. (10-K Consolidated Statements of Earnings; same URL/accession)

• customer classes: wholesale distributors, Health Systems & Providers, Payers & Insurers (10-K Business; same URL/accession)

AbbVie reports annual net revenues of $56.334 billion for FY2024 [ABBV10K; ABBV8K-Q4]. The company’s disclosed product-level revenue mix shows that the growth story is no longer Humira, but the newer immunology assets Skyrizi and Rinvoq.

Top disclosed product revenues and derived share of total net revenues, from AbbVie’s 10-K / Q4-2024 earnings materials [ABBV10K; ABBV8K-Q4]:

The top disclosed products above sum to approximately $42.98B, or about 76.3% of total net revenues. The balance consists of other disclosed and legacy products; the exact product-by-product remainder should be taken from the 10-K’s revenue table because this environment cannot retrieve the full table. Each of the dollar values above is company-reported and should be checked against the accession-level filing; I mark the exact accession number as needs primary source validation.

AbbVie’s 10-K describes the business as a single reportable segment focused on pharmaceutical products, but product-level disclosures group into therapeutic categories such as immunology, oncology, neuroscience, aesthetics, and other products [ABBV10K]. If grouped as such, AbbVie’s approximate 2024 mix using the above reported figures is:

• Immunology: about 47.3% of net revenue — Humira + Skyrizi + Rinvoq = $26.652B.
• Oncology: at least 9.6% of net revenue — Imbruvica + Venclexta = $5.418B, excluding newer oncology agents.
• Neuroscience: at least 14.8% of net revenue — Vraylar + Ubrelvy + Qulipta + Botox Therapeutic = $8.333B.
• Aesthetics: at least 4.6% of net revenue — Botox Cosmetic + Juvederm = $2.577B.
• Other/remaining: about 23.7% of net revenue — $13.354B, including other named products and legacy Allergan products.

These percentages are derived from the company-reported product figures above; the category assignment should be re-checked against AbbVie’s own therapy-area disclosures because the 10-K’s exact category labels and grouping may differ [ABBV10K].

The exact income-statement line items require validation against the 10-K’s consolidated statement of earnings. I am not confident enough to assert exact margins as verified, so the following margin values are marked needs primary source validation: I recall from the FY2024 10-K that cost of products sold was roughly $17B, implying a gross margin near 69%; selling, general and administrative expenses were large enough to bring operating margin to roughly 20%; and net margin was near 10%. These are not independent/corroborated calculations and should not be used for conviction without pulling the accession-specific 10-K.

What is more reliable from the cited product data is the portfolio mix shift: Humira, once the dominant high-margin product, declined from $14.404B in FY2023 to $8.991B in FY2024, while Skyrizi and Rinvoq together grew from $11.732B to $17.661B over the same period [ABBV10K; ABBV8K-Q4]. The gross-to-net dynamics differ by product, but the overall effect is that newer products must carry margin and volume growth to offset Humira’s erosion.

AbbVie monetizes through branded pharmaceutical product sales. Revenue is recognized when control transfers to the customer, typically upon delivery. The 10-K’s revenue recognition note describes gross-to-net reductions such as rebates, chargebacks, discounts, and returns; AbbVie records product revenue net of estimated rebates and discounts [ABBV10K]. Therefore, list price is not the actual net selling price.

End payers are mostly third-party payers — commercial insurers, Medicare, Medicaid, and government purchasers — not individual patients paying list price. AbbVie sells primarily to wholesalers/distributors, retailers, hospitals, clinics, and pharmacies [ABBV10K]. The filing names three wholesalers as major customers: McKesson, Cardinal Health, and Cencora. The exact percentage of gross revenues they represent in FY2024 is needs primary source validation, but the 10-K identifies them as significant customers [ABBV10K].

The buyer structure is two-layered:

1. Direct purchasers: AbbVie sells to wholesalers/distributors, chain drug stores, hospitals, clinics, and government purchasers [ABBV10K]. The three named U.S. wholesalers are McKesson, Cardinal Health, and Cencora [ABBV10K]. Outside the U.S., AbbVie sells to distributors and through affiliates.
2. End users and payers: patients receive products through prescriptions, but the economic buyers are mostly insurers, Medicare Part D/Medicaid, and to a lesser extent cash-pay patients for aesthetics.

Buyer archetypes by product:

• Rheumatologists, dermatologists, gastroenterologists for Humira, Skyrizi, and Rinvoq.
• Hematologists/oncologists for Imbruvica and Venclexta.
• Neurologists, psychiatrists, and primary care for Vraylar, Ubrelvy, Qulipta, and Botox Therapeutic.
• Aesthetic practitioners and plastic surgeons for Botox Cosmetic and Juvederm.

This buyer structure matters because demand is often not purely patient-driven. Formulary position and rebate contracts with PBMs can cause switches from one branded product to another or from Humira to a biosimilar without the patient initiating the change.

FY2025 revenue $61.16B (SEC 10-K). FY2026 guidance raised to ~$67.6B (+10.5% YoY). Q2 2026 revenue $16.99B (+10.2%). Adjusted operating margin ~48.3%, adjusted gross margin ~84.7%. Adj EPS FY2026: $13.87–$14.07.

FY2025 revenue $61.16B; Q2 2026 revenue $16.99B (+10.2% YoY vs. $15.42B in Q2 2025); 1H 2026 revenue $31.99B (+11.2% YoY vs. $28.77B), operating income $10.42B (+20.8%), net income $4.31B (+93.7%) — SEC companyfacts for 10-Q filed 2026-08-03. TTM gross margin 71.48%, operating margin 26.20%, net margin 9.81% — StockAnalysis financials page (SEC-derived data).

Post-Humira monetization is intact; the question is not whether AbbVie can sell more immunology drugs, but whether a competitor can spend the time and capital to match the CMC + clinical + regulatory stack before exclusivity rolls off.

• Immunology Q2 2026: $8.79B (+15.1% YoY). Skyrizi $5.51B (+24%), Rinvoq $2.53B (+24.5%). Together they now exceed Humira at its peak and represent ~52% of total revenue.
• Humira: $756M (-35.9% YoY) — the LOE cliff is material but fully absorbed. Net immunology growth of $1.6B YoY even after subtracting $424M of Humira erosion.
• Neuroscience: $3.23B (+20.3%) — Vraylar and Botox Therapeutic both >$1B quarterly.
• Raised FY2026 revenue guidance by $600M YTD (cumulative raises across Q1 and Q2). Operating beat of ~$0.10/share absorbed $0.14/share dilution from the $10.9B Apogee Therapeutics acquisition.
• Skyrizi substance patent to 2033 (US data protection ~2031); Rinvoq US exclusivity extended to 2037 via settlement. Combined, these two products have >$60B in cumulative patent-protected revenue runway.
• 97.4% of AbbVie revenue comes from products with patent/regulatory exclusivity through at least 2029 (company disclosure, Q2 2026 call).

• 1H26 revenue $31.99B vs. $28.77B (+11.2% YoY); Q2 revenue $16.99B (+10.2% YoY).
• 1H26 operating income $10.42B and net income $4.31B.
• FY2025 revenue $61.16B with 24.65% operating margin (StockAnalysis/SEC-derived).
• SEC cadence stayed active: 10-Q filed 2026-08-03; 8-K filed 2026-07-31; 8-K filed 2026-08-05 (submissions JSON).
• Prior closeout still governs the moat math: biosimilar replication needs roughly $1.0B–$2.0B and 6–9 years; year-1 biosimilar share is usually 10–30%, not instant generic collapse.

• On 2026-08-04 AbbVie entered an underwriting agreement for $10.0B of senior notes across eight tranches, and the 2026-08-06 424(b)(5) prospectus supplement says net proceeds are expected to be ~$9.93B after underwriting discounts and expenses.
• The same filings say the proceeds will fund a portion of AbbVie’s cash payment obligations for the Apogee Therapeutics acquisition, pay related fees/expenses, and may also be used for debt repayment or repurchase; the net proceeds also reduce commitments under AbbVie’s $10.0B 364-day delayed draw term loan tied to Apogee.
• Fixed-rate tranches total $9.5B at coupons of 4.50% to 6.10%; the weighted average fixed coupon is about 5.2%, implying roughly $493.9M/year of fixed coupon burden before the floating-rate tranche.
• AbbVie’s Q2 2026 10-Q reported 1H 2026 revenue of $31.992B, operating earnings of $10.422B, and interest expense, net of $1.324B.

The above revenue inputs are all from the same issuer. They are primary-source facts from AbbVie’s filings, but they are not corroborated by a second independent originating source. Where the requirement is strict two-source verification for load-bearing claims, these should be tagged single-source or cross-checked against a separate filing/audit or third-party payer data if used for conviction.